Carmustine DNA/RNA Synthesis inhibitor

Cat.No.S3669

Carmustine (bis-chloroethylnitrosourea, BCNU, BiCNU) is a cell-cycle phase nonspecific alkylating antineoplastic agent and used in the treatment of brain tumors and various other malignant neoplasms.
Carmustine DNA/RNA Synthesis inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 214.05

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 214.05 Formula

C5H9Cl2N3O2

Storage (From the date of receipt) 3 years, -20°C
CAS No. 154-93-8 Download SDF Storage of Stock Solutions

Synonyms bis-chloroethylnitrosourea, BCNU, BiCNU Smiles C(CCl)NC(=O)N(CCCl)N=O

Solubility

In vitro
Batch:

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03315520 Unknown status
Relapsed/Refractory Malignant Lymphomas
State Budgetary Healthcare Institution National Medical Surgical Center N.A. N.I. Pirogov Ministry of Health of Russia
January 22 2016 Phase 2
NCT01656980 Unknown status
Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma
Shandong Lanjin Pharmaceuticals Co.Ltd
August 2012 Phase 3
NCT01637753 Unknown status
Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma
Shandong Lanjin Pharmaceuticals Co.Ltd
June 2012 Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map